Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 124 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/22/2008 First Published: 7/1/1999


1.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15


2.		Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				12 to 55				Pharmaceutical / Industry				GC P#02.01.001 NCT00469729


3.		In-Vivo Activated T-Cell Depletion to Prevent GVHD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 to 75				Other				0705-20 IUCRO-0196 NCT00594308


4.		Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				2 to 55				NCI, NHLBI				385 BMT CTN 0402, U01 HL069294-05, NCT00406393

Last Modified: 7/10/2007 First Published: 5/1/2001


5.		Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				4 to 21				NCI				NCI-01-C-0125F NCT00020592

Last Modified: 5/14/2007 First Published: 11/1/2002


6.		Phase I/II Study of Immunologically Engineered, Filgrastim (G-CSF)-Mobilized, Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia Transformed From MDS, or Myeloproliferative Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				NCI				FHCRC-1628.00 NCI-H02-0099, NCT00049634

Last Modified: 10/21/2008 First Published: 8/24/2003


7.		Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Any age				NCI				FHCRC-1803.00 5606, NCT00068718


8.		Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				12 to 60				Pharmaceutical / Industry				CB001 NCT00089596

Last Modified: 10/21/2008 First Published: 10/25/2004


9.		Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 75				NCI, Pharmaceutical / Industry				FHCRC-1825.00 5605, SUPERGEN-FHCRC-1825.00, NCT00096161

Last Modified: 1/29/2008 First Published: 10/21/2005


10.		Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-HEM-05011-L OHSU-210, NCT00245037

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute